Genmab — Juli 2018
-
Trial represents ‘bold move’ for treatment of newly diagnosed myeloma - https://www.healio.com/hematology-oncology/myeloma/news/online/{1ebabaf8-6883-4567-8253-bc4ce2e72ecf}/trial-represents-bold-move-for-treatment-of-newly-diagnosed-myeloma
-
from Seattle Genetics Q2 2018 Results http://investor.seattlegenetics.com/phoenix.zhtml?c=124860&p=RssLanding&cat=news&id=2360357
-
Tisotumab Vedotin (TV) Program Activities
• Metastatic Cervical Cancer Trial Initiated: Seattle Genetics and Genmab initiated a phase 2 trial called innovaTV 204 in patients with recurrent and/or metastatic cervical cancer who have relapsed or progressed after standard of care treatment. The trial will enroll approximately 100 patients and is intended to potentially support registration under the FDA's accelerated approval pathway. -
God morgen.
-
God morgen til dagen hvor ALCYONE bliver indstillet til 1. linie godkendelse i Europa.......forhåbentlig....:-)
-
Go' morgen
-
Seattle Genetics (SGEN) Q2 2018 Results - Earnings Call Transcript https://seekingalpha.com/article/4190986-seattle-genetics-sgen-q2-2018-results-earnings-call-transcript?part=single
-
Our third late-stage program is tisotumab vedotin. which we're developing with Genmab. We've achieved two recent milestones. We've dosed the first patient in a pivotal trial for women with recurrent or metastatic cervical cancer. And we started a Phase 2 basket trial evaluating tisotumab vedotin in other solid tumors. These trials are intended to support an initial accelerated approval pathway in cervical cancer and inform opportunities to broaden the program.
-
Our third late-stage clinical program in our pipeline is tisotumab vedotin, or TV, which we are co-developing with Genmab. We recently treated the first patient with TV in the pivotal Phase 2 single-arm monotherapy trial called innovaTV 204 in women with second or third line cervical cancer. Target enrollment is approximately 100 patients and the primary endpoint is ORR. The trial is intended to support regulatory submission under the FDA's accelerated approval pathway
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind